Molecular Studies on Phospholipid-Binding Sites and Cryptic Epitopes Appearing on β 2 -Glycoprotein I Structure Recognized by Anticardiolipin Antibodies
Restricted accessOtherFirst published online February, 1995
Molecular Studies on Phospholipid-Binding Sites and Cryptic Epitopes Appearing on β 2 -Glycoprotein I Structure Recognized by Anticardiolipin Antibodies
HarrisENGharaviAEBoeyML. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet1983; 2: 1211–14.
2.
KoikeTSueishiHFunakiH. Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol1984; 56: 193–9.
HughesGRVHarrisENGharaviAE. The anticardiolipin syndrome. J Rheumatol1986; 13: 486–9.
5.
AshersonRAHarrisEN. Anticardiolipin antibodies: Clinical associations. Postgrad Med J1986; 62: 1081–7.
6.
LockshinMDDruzinMLGoeiS. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med1985; 313: 152–6.
7.
McNeilHPChestermanCNKrilisSA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol1991; 49: 193–280.
8.
McNeilHPSimpsonRJChestermanCN. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sc USA1990; 87: 4120–4.
9.
GalliMComfuriusMPMaassenC. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990; 335: 1544–7.
10.
MatsuuraEIgarashiYFujimotoM. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet1990; 336: 177–8.
11.
KoikeTMatsuuraE. What is the ‘true’ antigen for anticardiolipin antibodies?Lancet1991; 337: 671–2.
12.
MatsuuraEIgarashiYFujimotoM. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992; 148: 3885–91.
13.
BeversEMGalliMBarbuiT. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostasis1991; 66: 629–32.
14.
OostingJDDerksenRHWMBobbinkIWG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S - an explanation for their pathogenic mechanism?Thromb Haemostasis1993; 69: 1012.
15.
HuntJEMcNeilHPMorganGJ. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus1992; 1: 75–81.
16.
MatsuuraEIgarashiYYasudaT. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen-modified solid phase surface. J Exp Med1994; 179: 457–62.
17.
HuntJEKrilisSA. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol1994; 152: 653–9.
18.
MatsuuraEIgarashiMIgarashiY. Molecular definition of β2-glycoprotein I (β2-GPI) by dDNA cloning and inter-species differences of β2-GPI in alternation of anticardiolipin binding. Int Immunol1991; 3: 1217–21.
19.
IgarashiMMatsuuraEIgarashiY. Expression of anticardiolipin cofactor, human β2-glycoprotein I. by a recombinant baculovirus/insect cell system. Clin Exp Immunol1993; 93: 19–25.
20.
HashimotoYKawamuraMIchikawaK. Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol1992; 149: 1063–8.
21.
SchulzeHEHeideKHauptH. Uber ein bisher ubekanntes niedermolekulars β2-Globulin des Humanserums. Naturwissenschaftern1961; 48: 719–24.
22.
NakayaYSchaeferFJBrewerHCJr. Activation of human post heparin lipoprotein lipase by apolipoprotein H (β2-glycoprotein I). Biochem Biophys Res Commun1980; 95: 1168–72.
23.
LozierJTakahashiNPutmanFW. Complete amino acid sequence of human β2-glycoprotein I. Proc Natl Acad Sci USA1984; 81: 3640–4.
24.
SteinkassererAEstallerCWeissEH. Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein I. Biochem J1991; 277: 387–91.
25.
MehdiHNunnMSteelDM. Nucleotide sequence and expression of human gene encoding apolipoprotein H (β2-glycoprotein I). Gene1991; 108: 293–8.
26.
KatoHEnjyojiK. Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I: The presence of five sushi domains. Biochemistry1991; 30: 11687–94.
27.
SchouboeI. Inositolphospholipid-accelerated activation of prekallikrein by activated factor XII and its inhibition by β2-glycoprotein I. Eur J Biochem1988; 176: 629–36.
28.
PolzE. Isolation of a specific lipid binding protein from human serum by affinity chromatography using heparin-Sepharose. In: PeetersH, (ed.) Provides of Biological Fluids. Oxford, UK: Pergamon Press, 1988: 817–20.
29.
WurmH. β2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem1984; 16: 511–15.
30.
PolzEKostnerGM. The binding of β2-glycoprotein I to human serum lipoproteins. Distribution among density fractions. FEBS Lett1979; 102: 183–6.
31.
ShcouboeI. A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood1985; 66: 1086–91.
32.
NimpfJWurmHKostnerGM. β2-Glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis1987; 63: 109–14.
33.
NimpfJBeversEMBomansPH. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim Biophys Acta1986; 884: 142–9.
34.
HuntJESimpsonRJKrilisSA. Identification of a region of β2-glycoprotein I critical for lipid binding and anticardiolipin antibody cofactor activity. Proc Natl Acad Sci USA1993; 90: 2141–5.
35.
ShiWChongBHHoggPJ. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost1993; 70: 342–5.
36.
NomuraSKomiyamaYMatsuuraE. Binding of β2-glycoprotein I to platelet-derived microparticles. Br J Haematol1993; 85: 639.
37.
NomuraSFukuharaSKomiyamaY. β2-Glycoprotein I and anticardiolipin antibody influence factor Xa generation but not factor Xa binding to platelet-derived microparticles. Thromb Haemost1994; 71: 526–7.
38.
OostingJDDarksenRHWMEntjesHTI. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost1992; 67: 499–502.
39.
GalliMComfuriusPBarbuiT. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost1992; 68: 297–300.
40.
RoubeyRASPrattCWBuyonJP. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-gly-coporotein I. J Clin Invest1992; 90: 1100–4.
41.
SteinbergDWitztumJL. Lipoproteins and atherogenesis: Current concepts. J Am Med Assoc1990; 320: 915–924.
42.
HaberlandMEFongDChengL. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidaemic rabbits. Science1988; 241: 215–8.
BoydHCGownAMWolfbauerG. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyper-lipidemic rabbits. Am J Pathol1989; 135: 815–25.
45.
SalonenJTYla-HerttualaSYamamotoR. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet1992; 339: 883–7.
46.
VaaralaOAlfthanGJauhiainenM. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet1993; 341: 923–5.
